Glen Eagle Advisors’s Moderna MRNA Stock Holding History

Glen Eagle Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.99K	Buy	57 +10	+21%	+$517	﹤0.01%	816
2026 Q1	$2.39K	Hold	47	–	–	﹤0.01%	830
2025 Q4	$1.39K	Hold	47	–	–	﹤0.01%	927
2025 Q3	$1.21K	Buy	47 +10	+27%	+$279	﹤0.01%	977
2025 Q2	$1.02K	Hold	37	–	–	﹤0.01%	934
2025 Q1	$1.05K	Sell	37 -22	-37%	-$781	﹤0.01%	925
2024 Q4	$2.45K	Hold	59	–	–	﹤0.01%	846
2024 Q3	$3.94K	Hold	59	–	–	﹤0.01%	804
2024 Q2	$7.01K	Buy	59 +12	+26%	+$1.52K	﹤0.01%	710
2024 Q1	$5.01K	Sell	47 -5	-10%	-$504	﹤0.01%	764
2023 Q4	$5.17K	Hold	52	–	–	﹤0.01%	734
2023 Q3	$5.37K	Hold	52	–	–	﹤0.01%	714
2023 Q2	$6.32K	Sell	52 -6	-10%	-$800	﹤0.01%	703
2023 Q1	$8.91K	Buy	58 +10	+21%	+$1.65K	﹤0.01%	634
2022 Q4	$8.62K	Buy	48 +2	+4%	+$327	﹤0.01%	639
2022 Q3	$5.44K	Hold	46	–	–	﹤0.01%	691
2022 Q2	$6.57K	Hold	46	–	–	﹤0.01%	686
2022 Q1	$7.92K	Hold	46	–	–	﹤0.01%	661
2021 Q4	$11.7K	Hold	46	–	–	﹤0.01%	594
2021 Q3	$17.7K	Hold	46	–	–	0.01%	578
2021 Q2	$10.8K	Hold	46	–	–	﹤0.01%	680
2021 Q1	$6.02K	Hold	46	–	–	﹤0.01%	743
2020 Q4	$4.81K	Buy	46 +31	+207%	+$3.14K	﹤0.01%	749
2020 Q3	$1.06K	Buy	+15	New	+$1.05K	﹤0.01%	844

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Glen Eagle Advisors's MRNA Position: Q2 2026 in Review

Glen Eagle Advisors increased its Moderna (MRNA) stake by 21% in Q2 2026, buying an estimated $517 and bringing the position to 57 shares worth $3.99K. The position accounts for ﹤0.01% of the portfolio, ranked #816.

Glen Eagle Advisors first reported a position in MRNA in Q3 2020 and has held it in 24 quarters since. The position peaked at $17.7K in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Glen Eagle Advisors held 57 shares of Moderna worth $3.99K as of Q2 2026.
Glen Eagle Advisors bought 10 Moderna shares in Q2 2026, an estimated $517.
Moderna made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q2 2026, its #816 holding.
Glen Eagle Advisors first reported a position in Moderna in Q3 2020 and has held it in 24 quarters since.
Glen Eagle Advisors's Moderna position peaked at $17.7K in Q3 2021.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Glen Eagle Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.